Mankind Pharma Limited has informed the Exchange about Sale or disposal
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty Midcap 150 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma's board approved Q1 FY26 (quarter ended June 30, 2025) results. Standalone revenue from operations grew to ₹2,541.36 crore (vs ₹2,412.62 crore in Q1 FY25, restated), with profit after tax of ₹412.76 crore and EPS of ₹10. Consolidated revenue jumped to ₹3,570.35 crore (vs ₹2,867.85 crore), aided by the Bharat Serums and Vaccines (BSV) acquisition, while consolidated PAT was ₹444.62 crore. The board declared an interim dividend of ₹1 per share (100% on face value), with August 8, 2025 as the record date. The company also approved the acquisition of BSV's Women Health Rx branded generic business via slump sale and raising up to ₹1,000 crore through Commercial Papers on a private placement basis. Chief Marketing Officer Dr. Sanjay Koul resigned effective August 1, 2025. Auditors flagged an emphasis of matter on ongoing income tax proceedings involving disallowances of over ₹1,500 crore, which the company is contesting in appeal.
Positive near-term signals from revenue growth, an interim dividend, and the strategic BSV Women Health acquisition. However, consolidated PAT declined YoY partly due to higher finance costs and amortisation from the BSV deal, and the income tax dispute remains a key overhang that investors should monitor.